IBOV 166,934.20 ▼ 0.10% IPSA 11,042.67 ▲ 0.39% IPC MEX 64,397.45 ▼ 0.66% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL5.21▲ 0.47% USD/MXN17.02▼ 0.08% USD/CLP914.45▼ 0.02% USD/COP3,141▼ 0.15% USD/PEN3.37▼ 0.21% USD/ARS1,488▼ 0.28% USD/UYU40.33▲ 1.50% USD/PYG5,984▲ 2.22% USD/BOB11.54▼ 0.69% USD/DOP58.45▲ 0.55% USD/CRC446.12▲ 0.91% USD/GTQ7.62▲ 2.25% USD/HNL26.79▲ 0.54% USD/NIO36.62— 0.00% USD/VES769.14▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.70▲ 0.74% EUR/BRL6.05▲ 1.03% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 166,934.20 ▼ 0.10% IPSA 11,042.67 ▲ 0.39% IPC MEX 64,397.45 ▼ 0.66% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Sunday, August 16, 2026

Argentina Grants Emergency Approval to Pfizer/BioNTech Vaccine

By · December 23, 2020 · 2 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – Argentina’s medicine and food regulator granted on Tuesday, December 22nd, an emergency use for the Pfizer/BioNtech vaccine in the country. These vaccines are expected to arrive in Argentina sometime between January and March.

“The product presents an acceptable benefit-risk equilibrium, which enables awarding the registration and conditional authorization for the indicated purpose” was the statement from the Medicines, Food and Medical Technological National Administration, ANMAT, a rare organizations in the Argentine bureaucracy which enjoys international recognition for its rigorous scientific expertise.

Argentina's medicine and food regulator extended on Tuesday, December 22nd, an emergency use for the Pfizer/BioNtech vaccine in the country. These vaccines are expected to arrive in Argentina sometime between January and March.
Argentina’s medicine and food regulator granted an emergency use authorization for the Pfizer/BioNtech vaccine. (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Based on this authorization and the fact that some 6,000 Argentines volunteered to test the Pfizer vaccine, the Argentine government announced that a million and a half of the Pfizer vaccines will be reaching the country in the first half of next year.

In effect Anmat said that the authorization was extended for a year under the condition of “emergency registry”, similar to those extended in Europe and in the US. The contract will be signed by Argentina’s public health minister and will provide some 1,5 million vaccines between January and March 2021. Apparently the cost of each vaccine dose is estimated at 20 Euros, according to Argentine sources.

The announcement was made public when a special Aerolineas Argentinas flight departed from Argentina to Moscow in order to pick up the first batch of the Russian Sputnik V vaccine against the coronavirus.

”Today at 19:30 (01:30) on Wednesday Moscow time, a special flight will depart from Ezeiza [airport] for Moscow to bring to Argentina the first Sputnik V vaccines against COVID-19,” wrote the Argentine airline president Pablo Ceriani.

The mission involving an Airbus A330 plane, will take 40 hours with 20 participants involved. The vaccine will be packaged in thermo boxes with a temperature of minus 18 Centigrade maintained.

Earlier, the official Twitter account of the Russian vaccine reported that the Russian Direct Investment Fund and the government of Argentina had signed a contract to deliver 10 million of the first doses of the Sputnik V vaccine. Argentine President Alberto Fernandez stated that he will be the first in his country to get inoculated with the Russian vaccine.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.